Prognostic significance of changes in IL-12 secretion during cancer immunotherapy with IL-2: Preliminary considerations

International Journal of Immunotherapy

Volumn 13, Issue 1-2, 1997, Pages 17-23

  Lissoni, P ^a   Fumagalli, L ^b   Di Felice, G ^b   Mengo, S ^a   Mauri, E ^b   Merlini, D ^a   Meregalli, S ^a   Rovelli, F ^a   Barni, S ^a   Tancini, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b Chiron Italia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; NEOPTERIN; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; FEMALE; HUMAN; KIDNEY CANCER; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 7144251872     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rosenberg SA The immunotherapy and gene therapy of cancer. J Clin. Onc., 10 (2), 180, 1992
2. Banks R E , Patel PM., Selby PJ Interleukin-12: a new clinical player in cytokine therapy Br. J. Cancer, 71, 655, 1995
3. Wigginton J.M., Komschlies K.L , Back TC., et al. Administration of IL-12 with pulse IL-2 and the rapid and complete eradication of murine renal cell carcinoma J N C I , 88 (1), 38, 1996
4. Whittington R , Faulds D Interleukin-2. Drugs, 46, 446, 1993
5. Wanebo H J., Pace R., Hargett S , et al Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer, 57, 656, 1986
6. Lissoni P., Barni S Rovelli F, et al. Correlation of serum interleukin-2 levels, soluble interieukin-2 receptors and T lymphocyte subsets in cancer patients Tumori, 76, 14, 1990
7. Lissoni P, Barni S., Rovelli F, et al. Lower survival in metastatic cancer patients with reduced interleukinm-2 blood concentrations Oncology, 48, 125, 1991
8. Maltoni M., Pirovano M , Nanni O et al Biological indices predictive of survival in 519 Italian terminally ill cancer patients J Pain Symptom Manage, 13, 1, 1997.
9. Atzpodien J., Kirchner H. Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin. Wochenschr , 68, 1, 1990
10. Sullivan S.T., Lederer J.A., Morgan A.F, et al Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg., 222(4), 482, 1995.
11. Caligiuri M.A. Low-dose recombinant IL-2 therapy: rationale and potential clinical applications Sem. One., 20(6), Suppl. 9, 3, 1993.
12. Bogdan C , Vodovoz Y., Nathan CF. Macrophage deactivation by interleukin-10. J Exp Med., 174, 1549, 1991
13. D'Andrea A , Rengaraju M , Valiante N M , et al Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells J Exp. Med., 176(5), 1387, 1992.
14. Jankovic BD Neuroimmunomodulation Ann N Y. Acad. Sci., 741, 1, 1994
15. Tartour E., Dorval T, Mossen V, et al Serum Interleukin-6 levels and CRP correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br. J Cancer, 69, 911, 1994